Company intelligence / Profile preview
KYAN Technologies
Singaporekyantechnologies.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
KYAN Technologies employs its functional precision medicine platform, Optim.AI™, in clinical studies to personalize and optimize cancer treatment regimens. Their combinatorial drug sensitivity testing and AI-based analytics are currently used in clinical research with demonstrated ability to guide therapy choices in colorectal and breast cancer, with programs in early clinical development stages[1][3][4].
- Therapeutic areas
- OncologyNeurologyHematologyImmunology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on KYAN Technologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KYAN Technologies.